Clinical trial
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT03632941
Study timeline
Study start (actual)2019-03-01Date precision: day
Registry last updated2026-06-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
HER2+ Breast Cancerunresolved
Interventions
VRP-HER2BIOLOGICAL
PembrolizumabBIOLOGICAL
Sponsors & collaborators
Herbert Lyerlylead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03632941 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.